Weight-loss drug developer Metsera reveals wider loss in US IPO filing | Reuters

1. Metsera reports a $156.26 million loss in 2024's first nine months. 2. IPO proceeds will fund MET-097i clinical trials and operating costs. 3. Weight-loss drug market projected to reach $150 billion by 2030. 4. Investor interest is strong due to successful biotech IPOs last year. 5. World Health Organization may reconsider GLP-1 drug inclusion in 2025.